Core Insights - The 17th China Bio-Industry Conference opened in Wuhan, marking it as the largest and most influential professional event in China's bio-industry sector [1] - The conference showcased significant innovations, including the world's first plant-derived recombinant human serum albumin injection, Aofumin®, developed by Wuhan Heyuan Biotechnology Co., Ltd. [2] - The conference highlighted various groundbreaking products, including a visual intervention robot system and an implantable brain-computer interface chip, attracting considerable attention from attendees [5] Industry Developments - The conference featured the world's first clinical research candidate for oncolytic virus therapy, OH2 injection, developed by Wuhan Binhui Biotechnology Co., Ltd. [5] - The "China Bio-Economy Development Report 2025" was released, indicating that China's bio-economy industry remains the largest globally and is experiencing continuous growth [10] - Wuhan has established itself as a permanent host for the China Bio-Industry Conference since 2018, developing a comprehensive bio-pharmaceutical industry cluster with a scale exceeding 550 billion yuan [10]